OnKure Therapeutics, Inc.
OKUR
$3.98
$0.082.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -17.21% | 156.88% | 3.34% | 215.26% | 285.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.88% | 34.65% | 18.97% | 72.92% | 80.47% |
| Operating Income | 20.88% | -34.65% | -18.97% | -72.92% | -80.47% |
| Income Before Tax | 22.58% | -27.20% | -8.85% | -67.00% | -84.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.58% | -27.20% | -8.85% | -67.00% | -84.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.58% | -27.20% | -8.85% | -67.00% | -84.47% |
| EBIT | 20.88% | -34.65% | -18.97% | -72.92% | -80.47% |
| EBITDA | 20.95% | -35.09% | -19.09% | -73.74% | -81.37% |
| EPS Basic | 27.27% | 97.03% | 97.46% | 96.09% | -92.64% |
| Normalized Basic EPS | 23.02% | 97.03% | 97.34% | 96.09% | -82.01% |
| EPS Diluted | 27.27% | 97.03% | 97.46% | 96.09% | -92.64% |
| Normalized Diluted EPS | 23.02% | 97.03% | 97.34% | 96.09% | -82.01% |
| Average Basic Shares Outstanding | 6.44% | 4,180.58% | 4,181.81% | 4,175.25% | -4.23% |
| Average Diluted Shares Outstanding | 6.44% | 4,180.58% | 4,181.81% | 4,175.25% | -4.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |